Phenotypeca secures commercial contract with Isogenica

March 2022

Phenotypeca has won a significant commercial contract with Isogenica. Isogenica - specialists in single-domain biotherapeutics - will be using Phenotypeca’s innovative platform to optimise high-level secretion of correctly folded VHHs and deploy yeast-display for VHHs to accelerate drug candidate selection. The contract, which begins in April, will span a period of nine months.

The project builds on a growing strategic  relationship with Isogenica.